The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials

Feb 24, 2009Journal of affective disorders

Aripiprazole’s effectiveness and safety for treating schizoaffective disorder from combined clinical trial results

AI simplified

Psychedelic Science on OpenScience ↗PubMed ↗DOI ↗

Abstract

Aripiprazole led to a significantly greater improvement in the PANSS Total score compared to placebo (-15.9 vs. -3.4, p=0.038).

Patients receiving aripiprazole showed a greater reduction in positive symptoms as measured by the PANSS Positive subscale (-4.6 vs. -1.0, p=0.027).
No significant differences in negative symptoms or general psychopathology were observed between aripiprazole and placebo groups.
There were no significant changes in weight, glucose, or total cholesterol levels between the treatment and placebo groups.
Aripiprazole treatment was associated with a significant decrease in prolactin levels compared to placebo (-5.6 vs. -1.3, p<0.001).
Aripiprazole was found to be well tolerated in patients with schizoaffective disorder.

AI simplified

BACKGROUND: Schizoaffective disorder shares clinical characteristics with schizophrenia and affective disorders, with patients experiencing concurrent manic, mixed, or depressive episodes during psychosis. Because efficacy may be better in schizoaffective disorder than schizophrenia, this post-hoc analysis examines the efficacy, safety, and tolerability of aripiprazole in patients with schizoaffective disorder.

METHOD: Data were obtained from a sub-sample of subjects with schizoaffective disorder (randomized: aripiprazole n=123, placebo n=56) who participated in two 4-week, multicenter, double-blind trials of subjects with schizophrenia or schizoaffective disorder. Aripiprazole was administered at fixed doses of 15 mg/day, 20 mg/day, or 30 mg/day. Efficacy assessments included the Positive and Negative Syndrome Scale (PANSS) Total score, and the Positive, Negative, and General Psychopathology subscale scores. Safety and tolerability evaluations included incidence of treatment-emergent adverse events and extrapyramidal symptom assessments (SAS, BARS, and AIMS), and metabolic profile changes including weight and BMI.

RESULTS: A significantly greater improvement from baseline to endpoint was observed with aripiprazole compared with placebo on the PANSS Total (-15.9 vs. -3.4; p=0.038) and PANSS Positive subscale (-4.6 vs. -1.0; p=0.027). Differences between treatments were not significant for the PANSS Negative subscale score (-3.7 vs. -1.2; p=0.15) or PANSS General Psychopathology subscale score (-8.3 vs. -3.1; p=0.06). There were no statistically significant differences at endpoint between groups in the mean change from baseline to endpoint in weight, glucose, or total cholesterol, or on SAS, BARS, or AIMS scores. There was a statistically significant decrease in prolactin in subjects treated with aripiprazole compared with placebo (-5.6 vs. -1.3, p<0.001).

CONCLUSION: Aripiprazole was efficacious and well tolerated in patients with schizoaffective disorder.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: Results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the psychedelic science brief